Drinking Not Drowning: How to Deal With the Deluge of Potential Predictive Biomarker Approaches in Non-Small-Cell Lung Cancer.

about

Drinking Not Drowning: How to Deal With the Deluge of Potential Predictive Biomarker Approaches in Non-Small-Cell Lung Cancer.

Item

http://www.wikidata.org/entity/Q49188316

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Drinking Not Drowning: How to ...... in Non-Small-Cell Lung Cancer.

@en

Drinking Not Drowning: How to ...... in Non-Small-Cell Lung Cancer.

@nl

type

Item

label

Drinking Not Drowning: How to ...... in Non-Small-Cell Lung Cancer.

@en

Drinking Not Drowning: How to ...... in Non-Small-Cell Lung Cancer.

@nl

prefLabel

Drinking Not Drowning: How to ...... in Non-Small-Cell Lung Cancer.

@en

Drinking Not Drowning: How to ...... in Non-Small-Cell Lung Cancer.

@nl

P1476

Drinking Not Drowning: How to ...... in Non-Small-Cell Lung Cancer.

@en

P2093

D Ross Camidge

http://www.w3.org/2001/XMLSchema#string

P2860

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.

Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.

Validation of interobserver agreement in lung cancer assessment: hematoxylin-eosin diagnostic reproducibility for non-small cell lung cancer: the 2004 World Health Organization classification and therapeutically relevant subsets.

Distribution of EGFR Mutations in 10,607 Russian Patients with Lung Cancer.

Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis

A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma.

ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.

Biomarkers for Selection of Therapy for Adenocarcinoma of the Lung.

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors

P304

229-230

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JOP.2017.022772

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28399386

http://www.w3.org/2001/XMLSchema#string

P932

5791834

http://www.w3.org/2001/XMLSchema#string